Table 2

Improvement from baseline after one year treatment with etanercept or adalimumab
Pooled data Etanercept Adalimumab
Adjusted mean changes (95% CI) P-value Adjusted mean changes (95% CI) P-value Adjusted mean changes (95% CI) P-value
<4 years ≥4 years <4 years ≥4 years <4 years ≥4 years
BASDAI 3.2 (2.7, 3.7) 1.7 (1.1, 2.2) 0.001 3.1 (2.6, 3.6) 1.8 (1.1, 2.6) 0.008 3.2 (2.2, 4.3) 1.6 (0.9, 2.3) 0.02
BASFI 2.4 (2, 2.9) 1.2 (0.7, 1.6) 0.001 2.4 (1.9, 2.8) 1.2 (0.5, 1.8) 0.006 2.5 (1.5, 3.5) 1.3 (0.5, 2) 0.06
BASMI 0.3 (0, 0.6) −0.1 (−0.4, 0.2) 0.09 0.4 (0.1, 0.7) −0.02 (−0.5, 0.4) 0.16 0.02 (−0.6, 0.6) −0.1 (−0.5, 0.3) 0.74
ASDAS 1.6 (1.4, 1.8) 0.9 (0.7, 1.1) 0.001 1.5 (1.3, 1.8) 1.1 (0.8, 1.4) 0.04 1.7 (1.2, 2.1) 0.8 (0.5, 1.1) 0.003
CRP* 1.6 (1.5, 2) 1.6 (1.4, 1.8) 0.72 1.5 (1.4, 1.8) 1.6 (1.4, 2.0) 0.60 2.2 (1.6, 3.0) 1.5 (1.2, 1.8) 0.06
MRI SIJ 3.5 (2.9, 4.1) 3 (2.3, 3.6) 0.28 3.9 (3.3, 4.6) 3.7 (2.8, 4.6) 0.71 7.0 (3.8, 10.1) 2.7 (0.7, 4.7) 0.04

*Log-transformed CRP results were back transformed; p-value <0.05 was taken to indicate statistically significant differences between two groups; adjusted mean changes from baseline under treatment with etanercept or adalimumab (95% CI). Outcome differences were adjusted for baseline status (see Methods). BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASMI, Bath ankylosing spondylitis metrology index; ASDAS, ankylosing spondylitis disease activity score; CRP, C-reactive protein in mg/l; MRI, magnetic resonance imaging; SIJ sacroiliac joint.

Weiß et al.

Weiß et al. Arthritis Research & Therapy 2014 16:R35   doi:10.1186/ar4464

Open Data